Carey Kimmelstiel

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. ncbi [Alcohol septal ablation and hypertrophic cardiomyopathy]
    Carey Kimmelstiel
    Cardiac Catheterization Laboratory, Tufts Medical Center, Massachusetts 02111, USA
    Zhonghua Xin Xue Guan Bing Za Zhi 37:1074-7. 2009
  2. ncbi Restrictions on interactions between doctors and industry could ultimately hurt patients
    Carey Kimmelstiel
    Cardiac Catheterization Laboratory and Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    J Vasc Surg 54:12S-4S. 2011
  3. ncbi Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin
    Ping Zhang
    Hemostasis and Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA
    Circulation 126:83-91. 2012
  4. ncbi Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure
    Ravikiran Korabathina
    Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Catheter Cardiovasc Interv 80:498-502. 2012
  5. ncbi Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention
    Carey Kimmelstiel
    The Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Circ Cardiovasc Interv 4:171-9. 2011

Collaborators

Detail Information

Publications5

  1. ncbi [Alcohol septal ablation and hypertrophic cardiomyopathy]
    Carey Kimmelstiel
    Cardiac Catheterization Laboratory, Tufts Medical Center, Massachusetts 02111, USA
    Zhonghua Xin Xue Guan Bing Za Zhi 37:1074-7. 2009
    ..However, for a variety of clinical and logistical factors, such a trial is unlikely to ever be performed. For the foreseeable future, patient-specific therapy will depend on local expertise, patient comorbidities and preferences...
  2. ncbi Restrictions on interactions between doctors and industry could ultimately hurt patients
    Carey Kimmelstiel
    Cardiac Catheterization Laboratory and Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    J Vasc Surg 54:12S-4S. 2011
    ..The following article reviews the effects of legislation on medical innovation as well as the impact on continuing medical education...
  3. ncbi Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin
    Ping Zhang
    Hemostasis and Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA
    Circulation 126:83-91. 2012
    ..The thrombin receptor, PAR1, has recently emerged as a promising new target for therapeutic intervention in patients with acute coronary syndromes...
  4. ncbi Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure
    Ravikiran Korabathina
    Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Catheter Cardiovasc Interv 80:498-502. 2012
    ..We discuss risk factors that may have contributed to device thrombosis and raise concerns regarding the lack of a dedicated PFO closure device for clinical use in the United States...
  5. ncbi Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention
    Carey Kimmelstiel
    The Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Circ Cardiovasc Interv 4:171-9. 2011
    ..We tested the hypothesis that bivalirudin acts as an antiplatelet agent in PCI patients by preventing activation of PARs on the platelet surface...